O36.1135 Maternal care for Anti-A sensitization, third trimester, fetus 5

Name of the Condition

• Maternal care for Anti-A sensitization, third trimester, fetus 5
• ICD Code: O36.1135

Summary

This condition involves medical care and monitoring provided to a pregnant woman who has developed antibodies against the A antigen on red blood cells during the third trimester, specifically for a pregnancy with five fetuses. The care focuses on managing the potential risks to the fetuses and ensuring maternal health, particularly addressing the risk of hemolytic disease of the fetus and newborn (HDFN) in a multifetal pregnancy.

Causes

Anti-A sensitization occurs when an individual with type O blood (lacking A antigens) is exposed to A-positive blood, triggering the production of anti-A antibodies. In pregnancy, this exposure may happen during a previous pregnancy with an A-positive fetus, blood transfusion, or events causing fetal-maternal blood mixing. These antibodies can cross the placenta and attack the red blood cells of an A-positive fetus.

Risk Factors

• Previous pregnancy with an A-positive fetus
• Blood transfusion with A-positive blood
• Abdominal trauma during pregnancy
• Invasive prenatal procedures (e.g., amniocentesis)
• Prior miscarriage or ectopic pregnancy involving an A-positive fetus

Symptoms

• Often asymptomatic in the mother
• Fetal anemia, jaundice, or hydrops fetalis in severe cases
• Elevated bilirubin levels in the newborn

Diagnosis

Diagnosis involves blood typing and antibody screening to detect anti-A antibodies. Fetal monitoring may include ultrasound to assess for signs of anemia or hydrops fetalis, and specialized tests like Doppler ultrasonography or amniocentesis to evaluate fetal well-being. In multifetal pregnancies, each fetus may require individual assessment due to varying antibody exposure risks.

Treatment Options

Treatment focuses on close monitoring of maternal and fetal status. Interventions may include serial ultrasounds, fetal blood sampling, and intrauterine transfusions if severe anemia is detected. Post-delivery care involves monitoring newborn bilirubin levels and providing phototherapy or exchange transfusion if needed. Multifetal pregnancies may require additional coordination to manage care for each fetus.

Prognosis and Follow-Up

With appropriate monitoring and intervention, outcomes for both mother and fetuses can be favorable. Follow-up care includes regular prenatal visits, fetal surveillance, and postpartum monitoring of the newborns for signs of HDFN. Long-term prognosis depends on the severity of antibody exposure and timely management.

Complications

• Severe fetal anemia
• Hydrops fetalis (fluid accumulation in fetal tissues)
• Preterm birth
• Neonatal jaundice requiring intensive care
• Increased risk of fetal loss in severe cases

Lifestyle & Prevention

• Prenatal care to detect and manage sensitization early
• Avoiding unnecessary invasive procedures that may increase fetal-maternal blood mixing
• Blood typing and antibody screening in early pregnancy
• Consulting with a specialist in maternal-fetal medicine for high-risk pregnancies

When to Seek Professional Help

Seek immediate medical attention if experiencing symptoms like vaginal bleeding, severe abdominal pain, or reduced fetal movement. Regular prenatal visits are essential for monitoring antibody levels and fetal health, especially in multifetal pregnancies.

Tips for Medical Coders

Document the specific number of fetuses (five) and the trimester of care. Ensure that the medical record supports the need for specialized monitoring and interventions related to anti-A sensitization in a multifetal pregnancy. Code O36.1135 is used when the care is specifically for a third-trimester pregnancy with five fetuses affected by anti-A sensitization.